Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification
Authors:
Open Access
- 23 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Hematopathology
- Vol. 13 (2) , 79-88
Abstract
The percentage of blasts cells in the bone marrow (BM) of MDS patients is one of the key parameters for MDS classification and for the differential diagnosis with acute myeloid leukemia (AML). Currently, the gold standard to determine the blast percentage is conventional cytomorphology. To assess the possible impact of blast cell enumeration in BM biopsies from MDS patients on the final WHO classification using CD34 immunohistochemistry (IHC) a total of 156 BM samples from MDS and MDS-AML patients were studied and compared to blast counts by cytomorphology (CM). Eighty-nine BM aspirates were also studied by flow cytometry (FCM). Percentages of CD34+ blasts by IHC were determined blindly by two hematopathologists. Automated CD34-cell count was performed in 25 cases. Good overall agreement was found for CM and FCM with respect to critical blast thresholds (5%, 10%, 20%) (p < 0.05). However, in 17% of patients, CD34+ blast counts by IHC were higher as compared to CM with possible impact on MDS subclassification. In 7 of 21 AML patients, diagnosis was established on BM histology, while the blast percentage by CM was below the AML threshold. The assessment of CD34+ cells by IHC showed high interobserver agreement (Spearman R 0.95, p < 0.01), while automated CD34 counts were not optimal due to interference with other cellular and stromal elements. BM histology including CD34 IHC improves the diagnostic accuracy in MDS and AML. The quantification of blast cells should be based on the integration of all three methods for reliable disease classification and risk assessment.Keywords
Funding Information
- Karolinska Institute
This publication has 39 references indexed in Scilit:
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood, 2013
- Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromesHaematologica, 2012
- Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupLeukemia & Lymphoma, 2012
- Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular geneticsHaematologica, 2012
- Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET studyHaematologica, 2012
- Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patientsCytometry Part B: Clinical Cytometry, 2010
- Myelodysplastic SyndromesAmerican Journal of Clinical Pathology, 2009
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesHaematologica, 2009
- The WHO classification of MDS does make a differenceBlood, 2004
- Correlation Between the Percentages of Myeloblasts in Bone Marrow Obtained by Flow Cytometry and Manual Counting on Glass Slide Smears in 74 Hematologic PatientsLeukemia & Lymphoma, 2002